{"id":30980,"date":"2026-03-03T09:21:00","date_gmt":"2026-03-03T14:21:00","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/delaware-biotech-company-considers-sale-after-drug-trial-setback\/"},"modified":"2026-03-03T09:21:00","modified_gmt":"2026-03-03T14:21:00","slug":"delaware-biotech-company-considers-sale-after-drug-trial-setback","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/delaware-biotech-company-considers-sale-after-drug-trial-setback\/","title":{"rendered":"Delaware Biotech Company Considers Sale After Drug Trial Setback"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

A Delaware-area biotechnology company announced Tuesday it will explore selling itself or other strategic alternatives following disappointing results from a major drug trial.<\/p>

Theravance Biopharma revealed that its experimental medication ampreloxetine did not achieve its primary objectives in advanced clinical testing. The treatment was designed to help patients with multiple system atrophy, an uncommon condition that causes potentially dangerous blood pressure drops when patients stand up.<\/p>

According to the company’s announcement, participants who received the experimental treatment showed no significant symptom improvements when compared to those who received inactive placebo treatments.<\/p>

The biopharmaceutical firm has enlisted investment banking firm Lazard to assist with evaluating its options, though company officials cautioned that no transaction is guaranteed to occur.<\/p>

Trading of Theravance shares was suspended during pre-market hours following the announcement.<\/p>","protected":false},"excerpt":{"rendered":"

Theravance Biopharma announced Tuesday it will explore strategic options, potentially including selling the company, following disappointing results from a clinical trial. The company’s experimental medication for a rare blood pressure condition failed to show significant benefits over a placebo in late-stage testing.<\/p>\n","protected":false},"author":4,"featured_media":30979,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[834],"tags":[],"class_list":["post-30980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772547659101.png?fit=1920%2C1080&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-83G","jetpack-related-posts":[{"id":54865,"url":"https:\/\/tvdelmarva.com\/wp\/biogen-secures-china-drug-rights-in-massive-850m-partnership-deal\/","url_meta":{"origin":30980,"position":0},"title":"Biogen Secures China Drug Rights in Massive $850M Partnership Deal","author":"Admin","date":"April 20, 2026","format":false,"excerpt":"Massachusetts-based pharmaceutical company Biogen has struck a major agreement with Chinese biotech firm TJ Biopharma to obtain exclusive rights to market an experimental immune disease treatment in Greater China. The deal could be worth up to $850 million and gives Biogen global control over the promising kidney disease drug felzartamab.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776692197164.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":51252,"url":"https:\/\/tvdelmarva.com\/wp\/delaware-companys-new-drug-shows-promise-for-inflammatory-bowel-disease\/","url_meta":{"origin":30980,"position":1},"title":"Delaware Company’s New Drug Shows Promise for Inflammatory Bowel Disease","author":"Admin","date":"April 13, 2026","format":false,"excerpt":"Spyre Therapeutics announced Monday that their experimental medication SPY001 successfully reduced inflammation in patients with ulcerative colitis during a mid-stage clinical trial. The study found that 40% of participants achieved clinical remission after 12 weeks of treatment, with minimal side effects reported.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776081980773.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776081980773.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776081980773.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776081980773.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776081980773.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":68826,"url":"https:\/\/tvdelmarva.com\/wp\/experimental-drug-shows-promise-in-treating-rare-blood-vessel-disorders\/","url_meta":{"origin":30980,"position":2},"title":"Experimental Drug Shows Promise in Treating Rare Blood Vessel Disorders","author":"Admin","date":"May 19, 2026","format":false,"excerpt":"Relay Therapeutics announced Tuesday that their experimental drug zovegalisib successfully reduced abnormal blood vessel growths in about 60% of patients during mid-stage trials. The treatment showed significant symptom improvement with minimal side effects, offering hope for patients with rare vascular conditions.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779192417624.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779192417624.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779192417624.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779192417624.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779192417624.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":63116,"url":"https:\/\/tvdelmarva.com\/wp\/boston-company-reports-promising-results-for-rare-muscle-disease-treatment\/","url_meta":{"origin":30980,"position":3},"title":"Boston Company Reports Promising Results for Rare Muscle Disease Treatment","author":"Admin","date":"May 7, 2026","format":false,"excerpt":"A Boston-based pharmaceutical company announced Thursday that its experimental drug showed significant improvement in muscle function for children suffering from Duchenne muscular dystrophy. The treatment demonstrated statistically meaningful results in helping young patients stand up faster, a key indicator of muscle strength in this fatal genetic condition.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778158288710.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778158288710.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778158288710.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778158288710.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778158288710.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":68724,"url":"https:\/\/tvdelmarva.com\/wp\/swedish-biotech-secures-134m-european-licensing-deal-for-kidney-drug\/","url_meta":{"origin":30980,"position":4},"title":"Swedish Biotech Secures $134M European Licensing Deal for Kidney Drug","author":"Admin","date":"May 19, 2026","format":false,"excerpt":"Hansa Biopharma announced a major licensing agreement worth up to $134 million with SERB Pharmaceuticals for its kidney transplant medication Idefirix across European markets. The deal strengthens the Swedish company's financial position ahead of a potential U.S. drug approval decision expected in December.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779179728821.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":43887,"url":"https:\/\/tvdelmarva.com\/wp\/delaware-based-incyte-reports-promising-results-for-new-skin-disease-treatment\/","url_meta":{"origin":30980,"position":5},"title":"Delaware-Based Incyte Reports Promising Results for New Skin Disease Treatment","author":"Admin","date":"March 28, 2026","format":false,"excerpt":"Delaware pharmaceutical company Incyte announced Saturday that its experimental medication povorcitinib demonstrated sustained symptom improvement for patients with a painful chronic skin condition. The once-daily pill showed significant benefits in late-stage clinical studies, with over 70% of participants experiencing substantial reduction in painful skin lesions after more than a year\u2026","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774725745606.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774725745606.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774725745606.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774725745606.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774725745606.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/30980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=30980"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/30980\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/30979"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=30980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=30980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=30980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}